Guerbet

2020 Half-year results

2020 half-year results

• Revenue affected by the COVID crisis
  • -9.2% at current exchange rates at €363.7 million
  • -8.4% at constant exchange rates (CER)¹ at €367.1 million

• Satisfactory results in the midst of COVID
  • Strict management of operating costs
  • EBITDA margin rate of 14.7% of revenue
  • Operating income of €25.4 million 
  • Net income of €8.2 million

• Improvement of the already very solid financial structure
  • Sharp improvement in WCR
  • Cash flow generation increase
  • Net debt decrease

• Continued transformation of the Group
  • Development strategy roadmap maintained: diagnostic imaging, interventional imaging, digital solutions, and artificial intelligence
  • Reinforcement of the Executive Committee

• 2020 objectives: EBITDA margin around 14%
  • Second-half revenue comparable with the first half, leading to a decrease of approximately 10% over the year at CER
  • Long-term reduction of structural costs, improving operational leverage
  • Acceleration of the transformation

Villepinte, September 23, 2020 – Guerbet (FR0000032526), a global specialist in contrast agents and solutions for medical imaging, announced its consolidated results for the first half of 2020.

On the occasion of this publication, David Hale, Chief Executive Officer of Guerbet, stated: “Together we’ve shown agility and exemplary resilience during this unusual period. In that respect, I’d like to give warm thanks to all our staff. We’ve also implemented strict budgetary discipline to return to our path to sustainable development. During this period, we continued the roadmap on our promising projects: continued R&D, digitization, and an active search for acquisitions in Interventional Imaging. With a portfolio of quality products in growing markets, a reinforced Executive Committee, and a solid financial structure, all the pieces are there to speed up our profitable growth once business will be back to normal”.